Aravive
Batiraxcept, a soluble AXL receptor decoy protein that inhibits AXL signaling
- Sector
- Biotech
- Headquarters
- HOUSTON, TX
- Founded
- 2008
- Latest Form D
- $41.6M, Oct 2022
- Total capital
- $156M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $156M
- 8 Form D · last Oct 2022
- 48 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 8 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 8th filing$41.6M
- Private capital raisedForm D · SEC · 7th filing$55M
- Private capital raisedForm D · SEC · 6th filing$10M
- Private capital raisedForm D · SEC · 5th filing$10M
- Private capital raisedForm D · SEC · 4th filing$12.5M
- Private capital raisedForm D · SEC · 3rd filing$8M
- Private capital raisedForm D · SEC · 2nd filing$4.6M
- Private capital raisedForm D · SEC · 1st filing$14.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Amato B. GiacciaDirectorNamed in SEC Form D filings
- Eric B. ZhangDirectorNamed in SEC Form D filings
- Fredric N. EshelmanExecutive Officer, DirectorNamed in SEC Form D filings
- Gail McIntyreExecutive Officer, DirectorNamed in SEC Form D filings
- John A. HohneckerDirectorNamed in SEC Form D filings
- Leonard Scott DoveExecutive OfficerNamed in SEC Form D filings
Show all 11 people
- Michael W. RogersDirectorNamed in SEC Form D filings
- Peter T.C. HoDirectorNamed in SEC Form D filings
- Robert B. GellerExecutive OfficerNamed in SEC Form D filings
- Rudy N. HowardExecutive OfficerNamed in SEC Form D filings
- Sigurd C. KirkDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 8- PendingMethods Of Treating Locally Advanced Or Metastatic Pancreatic Adenocarcinoma Using Axl Decoy Receptors As First-line TherapyUSPTOApplication 18690722
- PendingMethods Of Treating Metastatic Cancers Using Axl Decoy ReceptorsUSPTOApplication 18228879
- PendingDiagnostic Methods For Cancer Using Axl Decoy ReceptorsUSPTOApplication 18016765
Show all 8 patent records
- Methods Of Treating Locally Advanced Or Metastatic Pancreatic Adenocarcinoma Using Axl Decoy Receptors As First-line TherapyNov 14, 2024 · Application 18690722Pending
- Methods Of Treating Metastatic Cancers Using Axl Decoy ReceptorsJan 11, 2024 · Application 18228879Pending
- Diagnostic Methods For Cancer Using Axl Decoy ReceptorsSep 7, 2023 · Application 18016765Pending
- METHODS OF TREATING CLEAR CELL RENAL CELL CARCINOMA (ccRCC) USING AXL DECOY RECEPTORSMar 16, 2023 · Application 17790282Pending
- Methods Of Treating Locally Advanced Or Metastatic Pancreatic Adenocarcinoma Using Axl Decoy Receptors As First-line TherapyApplication PCTUS2022043234Pending
- Diagnostic Methods For Cancer Using Axl Decoy ReceptorsApplication PCTUS2021042124Pending
- Methods Of Treating Clear Cell Renal Carcinoma (ccrcc) Using Axl Decoy ReceptorsApplication PCTUS2021012176Pending
- Methods Of Treating Immunoglobulin A Nephropathy (igan) Using Axl Decoy ReceptorsApplication PCTUS2020022860Pending
Related companies, and why
- Axelyf, Inc.Similar federal contract value in Biotech · null in contracts
- CURADEL SURGICAL INNOVATIONS, INC.Similar federal contract value in Biotech · null in contracts
- Immorta Bio, Inc.Similar federal contract value in Biotech · null in contracts
- SonoTheraSimilar federal contract value in Biotech · null in contracts
- Entrada TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Pelage PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .